Omalizumab shows superior efficacy to dupilumab in reducing symptoms in patients with chronic spontaneous urticaria.
On the heels of a Type A meeting with FDA’s Center for Biologics and Research (CBER), Moderna’s seasonal influenza vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results